A Multicenter Prospective Clinical Trial of 68Gallium PSMA HBED-CC PET-CT Restaging in Biochemically Relapsed Prostate Carcinoma: Oligometastatic Rate and Distribution Compared With Standard Imaging.


Department of Nuclear Medicine and PET, Sir Charles Gairdner Hospital, Perth, Australia; Molecular Imaging and Therapy Service (Nuclear Medicine), Royal Perth Hospital and Fiona Stanley Hospital, Perth, Australia. Electronic address: [Email]


The purpose of this study is to assess the utility of 68Gallium prostate-specific membrane antigen (PSMA) Division of Radiopharmaceutical Chemistry (DKFZ)-PSMA-11 positron emission tomography (PET)-computed tomography (CT), compared with standard imaging, in the detection of recurrent prostate carcinoma in patients with biochemical relapse to determine the prevalence of oligometastatic disease recurrence and its distribution.

OUR Recent Articles